Determine the Clinical Benefit Rate (CBR) at 24 weeks amongst patients receiving triple therapy with ribociclib + everolimus + exemestane, for advanced/metastatic HR+, HER2-negative breast cancer following progression on CDK 4/6 inhibitor.
Clinical Trial Information
Trial Contact: Hollenbach, Georgina; Pelley, Jennifer; Morales, Leticia
Age Group: Adult
Phase: Drug: Phase II
Principal Investigator: Rebecca L. Moroose, MD
Secondary Protocol No: TRIO TRINITI
Applicable Disease Sites: Breast Cancer